TL;DR
This study presents the largest series to date characterizing papillary craniopharyngiomas (PCPs) treated with the expanded endonasal approach (EEA). It introduces a novel classification system for PCPs based on imaging and intraoperative findings, revealing distinct clinical presentations and outcomes for each type, with Type II (suprasellar/intra-suprasellar, 3V floor invasive) showing a higher risk of recurrence and poorer quality of life.
What Problem Does This Paper Address?
Craniopharyngiomas (CPs) are rare tumors arising from remnants of Rathke's pouch. While the expanded endonasal approach (EEA) has become a preferred method for their removal due to its minimally invasive nature and improved visualization, a comprehensive understanding of papillary CPs (PCPs), a less common subtype, remains limited. Existing classifications of CPs are often based on broader categories or solely on imaging, lacking detailed intraoperative correlation. This gap makes it challenging to predict treatment outcomes and tailor surgical strategies for PCPs, particularly those located within or invading the third ventricle. This paper aims to address this by providing a detailed clinical characterization of PCPs treated with EEA, introducing a new classification system, and analyzing the associated outcomes.
Methods
The study retrospectively analyzed 101 patients with PCPs who underwent EEA surgery. A key methodological contribution is the classification of PCPs into three types based on a combination of preoperative MRI and intraoperative findings during EEA:
- Type I: Suprasellar/intra-suprasellar with an intact third ventricle (3V) floor.
- Type II: Suprasellar/intra-suprasellar with invasion or unclear separation from the 3V floor.
- Type III: Primarily within the third ventricle, with an intact 3V floor.
The researchers collected data on patient demographics, preoperative symptoms, endocrine status, imaging characteristics, surgical approach, extent of resection (gross total resection - GTR), postoperative quality of life (Karnofsky Performance Status - KPS), and tumor recurrence. Statistical analyses, including chi-square tests, t-tests, and multivariate logistic regression, were employed to compare characteristics between the three types and identify risk factors for recurrence.
Datasets
The study utilized a dataset of 101 patients diagnosed with papillary craniopharyngiomas who underwent surgery at Beijing Tiantan Hospital between September 2019 and December 2022. This represents the largest series of PCPs treated with EEA to date. No external datasets were used for training or evaluation.
Key Insights and Ideas
- Novel PCP Classification: The introduction of a three-type classification system (Type I, II, III) based on both imaging and intraoperative EEA findings is a significant contribution, offering a more nuanced understanding of PCP subtypes and their anatomical relationships.
- Type II as a High-Risk Subtype: Type II PCPs, characterized by invasion of the third ventricle floor, emerged as a critical subtype. These tumors were associated with a higher incidence of visual impairment, a worse postoperative quality of life, and were identified as an independent risk factor for tumor recurrence.
- EEA Efficacy for Intra-Third Ventricle PCPs: The study demonstrates that EEA is a safe and effective approach for removing even intra-third ventricle PCPs (Type III), challenging previous assumptions about the limitations of endoscopic approaches for such lesions.
- Distinct Clinical Manifestations by Type: Different PCP types presented with varying symptoms. Type III PCPs were associated with younger age, and more prominent headaches and memory decline, likely due to their location within the third ventricle and potential for CSF obstruction. Type II PCPs showed a higher rate of visual impairment.
- Tumor Texture and Adhesion: The study suggests that tumor texture (cystic vs. solid) might not be as critical for surgical adhesion and resection rates as previously thought, contrary to some prior research.
Key Results
- Tumor Distribution: Out of 101 cases, 36.64% were Type I, 51.49% were Type II, and 12.87% were Type III.
- Age and Symptoms: Type III patients were significantly younger (mean age 40.46 ± 14.15) and experienced more headaches and memory decline. Type II patients had a higher rate of visual impairment (80.77%).
- Resection Rates: Gross total resection (GTR) was achieved in 90.10% of patients, with no significant difference in GTR rates among the three types.
- Quality of Life: Significant differences in postoperative quality of life were observed, with Type III patients showing the highest rate of good quality of life (92.31% KPS > 70).
- Recurrence: 12.87% of tumors recurred within a mean follow-up of 38 months. Type II PCPs (OR 5.826) and previously relapsed patients were independent risk factors for recurrence.
Limitations and Future Work
The authors acknowledge several limitations:
- Retrospective Design: The study is retrospective, which can introduce selection bias.
- Sample Size: While the largest series of PCPs treated with EEA to date, the sample size for Type III PCPs is relatively small.
- Short Follow-up: The follow-up duration was short (mean 38 months), with some patients still within their follow-up period.
Future work could involve longer-term follow-up studies to further validate recurrence rates and long-term outcomes. Expanding the cohort, particularly for Type III PCPs, would strengthen the statistical power. Further investigation into the specific mechanisms driving recurrence in Type II PCPs could also be beneficial.
Summary updated